We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Total Marrow Irradiation & Autologous Stem Cell Transplantation for Relapsed or Refractory Myeloma (TMI-ASCT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00800059
Recruitment Status : Recruiting
First Posted : December 1, 2008
Last Update Posted : July 27, 2015
Information provided by (Responsible Party):
Ottawa Hospital Research Institute

Brief Summary:
The investigators hypothesize that conformal radiation will allow the administration of higher doses of external beam radiation to marrow based malignancies than total body irradiation (TBI)without increasing the toxicity to normal tissues beyond that induced by TBI. Further,the investigators hypothesize that this will result in an improvement in disease response and disease control for patients with multiple myeloma. This is a dose escalation study of TMI with the primary objective of determining the maximum tolerated dose of TMI when followed by aHSCT in patients with relapsed or refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Radiation: Total Marrow Irradiation Phase 1 Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 27 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Dose Escalation Study of Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) for the Treatment of Relapsed or Refractory Multiple Myeloma (MM)
Study Start Date : November 2008
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treatment
Treatment with TMI and autologous Stem Cell transplant
Radiation: Total Marrow Irradiation
Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
Other Name: TMI

Primary Outcome Measures :
  1. To determine the maximum tolerated dose of TMI when followed by aHSCT in patients with relapsed or refractory multiple myeloma [ Time Frame: 30 days from the time of aSCT ]

Secondary Outcome Measures :
  1. The frequency and timing of engraftment following TMI and aHSCT [ Time Frame: within 30 days of aHSCT ]
  2. The early morbidity and mortality associated with TMI and aHSCT [ Time Frame: 30 days from aHSCT ]
  3. The intermediate morbidity and mortality associated with TMI and aHSCT [ Time Frame: 100 days from aHSCT ]
  4. The late morbidity of TMI [ Time Frame: Beyond 6 months after transplantaton ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • A subject must meet all of the following criteria to be eligible for the study. These will be evaluated within the four weeks prior to enrolment.
  • Subject must have primary refractory or relapsed multiple myeloma.
  • Subject must have a measurable serum or urine monoclonal gammopathy at the time of their latest relapse.
  • Subject must meet institutional guidelines for autologous HSCT with adequate renal, cardiac, pulmonary and hepatic function.
  • An autologous hematopoietic stem cell graft containing more than 2.5 x 106 CD34+ cells/kg must be cryopreserved and available for transplantation.
  • Subject must be of age more than 18 and less than 60 years.
  • Subject must have an ECOG performance score of 0,1, or 2.
  • Subject must have the ability to comply with the protocol visit schedule and other protocol requirements.

Exclusion Criteria:

  • A subject meeting any of the following criteria is not eligible for participation in the study:
  • Subject with non-secretory multiple myeloma or any plasma cell disorders other that MM.
  • Subjects that have not received previous therapy with adequate intense corticosteroids for multiple myeloma.
  • Subjects with a severely limited life expectancy by concomitant illness, defined as a life-expectancy of less than 6 months.
  • Subjects who have previously received radiation treatments or other neoplastic disorders.
  • Subjects with a history of non-compliance in other studies.
  • Pregnant or lactating female subjects.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00800059

Canada, Ontario
The Ottawa Hospital Recruiting
Ottawa, Ontario, Canada, K1H 8L6
Contact: Harold Atkins, MD       hatkins@ohri.ca   
Principal Investigator: Rajiv Samant, MD         
Sponsors and Collaborators
Ottawa Hospital Research Institute
Principal Investigator: Harold L Atkins, MD Ottawa Hospital Research Institute

Responsible Party: Ottawa Hospital Research Institute
ClinicalTrials.gov Identifier: NCT00800059     History of Changes
Other Study ID Numbers: 2008519-01H
First Posted: December 1, 2008    Key Record Dates
Last Update Posted: July 27, 2015
Last Verified: July 2015

Keywords provided by Ottawa Hospital Research Institute:

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases